Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Kana Nagashima,Shohei Kikuchi,Satoshi Iyama,Chisa Fujita,Akari Goto,Hiroto Horiguchi,Masayoshi Kobune

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

2020

Kana Nagashima
Shohei Kikuchi
Satoshi Iyama
Chisa Fujita
Akari Goto
Hiroto Horiguchi
Masayoshi Kobune

Brentuximab vedotin monotherapy for late-relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Keywords:

Internal medicine
Medicine
Brentuximab vedotin
Classical Hodgkin lymphoma
Oncology
Pathology
Late Relapse
first remission
Cardiology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations